Lercanidipina Aurobindo

Lercanidipine, the active ingredient in Lercanidipina Aurobindo, is a calcium channel blocker presented as an oral tablet formulation for systemic administration. It works by relaxing vascular smooth muscle, thereby reducing peripheral resistance and helping to control hypertension in adult patients.

GNH USA supplies Lercanidipina Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide under appropriate regulatory standards. The company ensures consistent quality, traceability and on‑time delivery across global markets. Its supply chain adheres to WHO GMP guidelines and supports local regulatory submissions.

Lercanidipine acts on the cardiovascular system to lower elevated arterial pressure in several hypertension subtypes. - Essential hypertension: reduces systolic and diastolic blood pressure in adults. - Isolated systolic hypertension: improves pulse pressure control. - Secondary hypertension: assists in managing blood pressure when caused by other medical conditions.

Lercanidipine may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate pain often occurring shortly after dosing. - Flushing: sensation of warmth and redness, especially on the face. - Peripheral edema: swelling of the ankles or lower legs. - Dizziness or light‑headedness, particularly when standing quickly. - Fatigue: feeling unusually tired without exertion. - Tachycardia: increased heart rate in some patients.

Serious or Rare Side Effects: - Angioedema: swelling of the face, lips, tongue, or throat that may compromise breathing. - Severe hypotension: marked drop in blood pressure causing fainting or shock. - Myocardial infarction: rare occurrence of heart attack, especially in patients with pre‑existing coronary disease. - Hepatic injury: abnormal liver function tests or hepatitis. - Severe allergic reactions: rash, itching, or anaphylaxis.

Before initiating therapy, clinicians should evaluate patient history and monitor for specific concerns. - Blood pressure monitoring: check regularly to ensure therapeutic response and avoid excessive lowering. - Discontinuation: avoid abrupt cessation; taper if clinically indicated. - Hepatic impairment: use with caution and consider dose adjustment. - Pregnancy and lactation: consult a physician; benefits must outweigh potential risks. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lercanidipine can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma concentrations and risk of hypotension. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy by lowering drug levels.

Moderate Interactions (Monitor Closely):\n- Beta‑blockers: additive blood‑pressure‑lowering effect, may cause bradycardia. - Diuretics: enhanced antihypertensive response, monitor electrolytes. - Grapefruit juice: can increase lercanidipine exposure, advise patients to limit intake.